ASCL2 and head and neck squamous cell carcinoma: Collectively, these findings suggest that inhibiting mutant FAT1 reduces CPT1A levels by downregulating the AKT‐ASCL2 signaling axis, thereby reducing FAO and leading to LDs and ROS accumulation in HNSCC cells (Figure7).